2026-04-18T02:19:19Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/133702025-07-09T04:36:24Zcom_2072_378070com_2072_378040col_2072_378092

2025-07-09T04:36:23Z urn:hdl:11351/13370 A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study Murphy, Danielle A. Pu, Jie Kopetz, Scott Ciardiello, Fortunato Desai, Jayesh Van Cutsem, Eric Tabernero, Josep Anomalies cromosòmiques Recte - Càncer - Tractament Còlon - Càncer - Tractament DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación Colorectal cancer; Mutation Càncer colorectal; Mutació Cáncer colorrectal; Mutación What is this summary about? This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study. What were the results? Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes. The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived. What do the results of the study mean? The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors. This manuscript was funded by Pfizer. 2025-07-09T04:36:23Z 2025-07-09T04:36:23Z 2025-07-08T10:52:11Z 2025-07-08T10:52:11Z 2025 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13370 Future Oncology;21(14) https://doi.org/10.1080/14796694.2025.2498880 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Taylor & Francis Scientia